Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Treatment Outcomes in Patients with Hodgkin Lymphoma Treated with Conventional Therapy.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026
Same author

Corrosion behavior of selective laser melted NiTi shape memory alloy.

Scientific reports·2026
Same author

Melorheostosis Incidentally Detected during Staging of Colon Carcinoma.

Radiology. Imaging cancer·2026
Same author

Molecular Interactions Between Dimethylated Arginine and the Nitric Oxide Axis Unveil Programmed Death-Ligand 1 (PD-L1) Signaling Signatures in Gastric Cancer.

Cureus·2026
Same author

Impact of pre-operative frailty on hospital length of stay in major abdominal oncological surgeries: A prospective, observational study.

Indian journal of anaesthesia·2026
Same author

Predictive value of lymph node ratio on survival outcomes in esophageal squamous cell carcinoma: A tertiary cancer centre experience.

Journal of cancer research and therapeutics·2026

Related Experiment Video

Updated: May 21, 2026

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

Centchroman regresses mastalgia: a randomized comparison with danazol.

Prakash Lakhmichand Tejwani, Anurag Srivastava, Hrishikesh Nerkar

    The Indian Journal of Surgery
    |June 2, 2012
    PubMed
    Summary

    Centchroman effectively manages mastalgia (breast pain), showing superior pain reduction compared to Danazol. This safe and inexpensive drug offers a promising alternative for women experiencing breast pain.

    Keywords:
    AntiestrogenBreast painCentchromanDanazolMastalgiaNon-inferiority trialRandomized trial

    More Related Videos

    Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis
    05:36

    Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis

    Published on: October 4, 2024

    Related Experiment Videos

    Last Updated: May 21, 2026

    Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
    07:36

    Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

    Published on: December 23, 2022

    Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis
    05:36

    Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis

    Published on: October 4, 2024

    Area of Science:

    • Reproductive endocrinology
    • Pharmacology
    • Clinical medicine

    Background:

    • Mastalgia, or breast pain, affects many women and can significantly impact quality of life.
    • Current treatments for mastalgia include medications like Danazol, which can have side effects.
    • Centchroman, a non-steroidal contraceptive, has been investigated for its potential in managing mastalgia.

    Purpose of the Study:

    • To evaluate the effectiveness of Centchroman in controlling mastalgia.
    • To compare the efficacy of Centchroman with Danazol in mastalgia treatment.
    • To determine if Centchroman is a suitable alternative to Danazol for mastalgia.

    Main Methods:

    • A randomized controlled trial was conducted involving 81 patients with mastalgia.
    • Patients were randomized to receive either Centchroman (42 patients) or Danazol (39 patients) for 12 weeks.
    • Pain was assessed using the Visual Analogue Scale (VAS) at baseline, 12 weeks, and 24 weeks.

    Main Results:

    • Centchroman group: 89.7% achieved a pain score reduction to ≤3 at 12 weeks (p<0.001).
    • Danazol group: 69.44% achieved a pain score reduction to ≤3 at 12 weeks (p<0.001).
    • At 24 weeks, Centchroman demonstrated significantly greater pain reduction compared to Danazol (p=0.019).

    Conclusions:

    • Centchroman is an effective treatment for mastalgia.
    • Centchroman offers a safe and inexpensive alternative to Danazol for managing breast pain.
    • The study supports the use of Centchroman for mastalgia control.